OncoMatch/Clinical Trials/NCT05440149
The Postoperative Radiotherapy in N1 Breast Cancer Patients
Is NCT05440149 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for radiotherapy.
This study is a multicenter, randomized, phase 3 clinical trial in patients with breast cancer, randomizing radiotherapy group (postmastectomy radiation therapy (PMRT)/whole breast irradiation plus regional radiotherapy (WBI+regional RT) versus and no PMRT/WBI alone group. This is a non-inferiority study aiming that there is no significant difference in the 7-year disease-free survival rate between the two groups.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Allowed: ESR1 hormone receptor positive
Patients undergoing or planning to undergo hormone therapy in the case of hormone receptor positive
Allowed: HER2 (ERBB2) positive
Patients who have received or are expected to undergo targeted therapy in the case of human epidermal growth factor receptor(HER)-2 positive
Disease stage
Required: Stage PN1
stage pN1 after surgery on histopathologic examination; Patients with stage T4 [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: neoadjuvant chemotherapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05440149 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior neoadjuvant chemotherapy, radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage PN1 is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages